ribavirin

Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS

BELGRADE, SERBIA, July 23 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sc...

Hard To Treat Diseases (HTDS) Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin

BELGRADE, SERBIA, July 1 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ( www.htdsmedical.com ) Chief Scientist with its Slavica BioChem subsidiary, Dr. Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the p...

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage. This treatment technique also improved the response rates of African American patients, whose outcomes have...

Hard to Treat Diseases, Inc. (HTDS) Reports on New Uses For Ribavirin

BELGRADE, SERBIA, May 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant new advances recently announced regarding the drug Ribavirin; one of the drugs with which t...

Valeant Pharmaceuticals Reports Second Quarter Financial Results

...nce revenue for the three and six months ended June 30, 2009 relates to ribavirin royalty of $12.6 million and $25.8 million, alliance revenue from the G...iance revenue for the three and six months ended June 30, 2008 includes ribavirin royalties of $14.8 million and $27.5 million, respectively and in the s...

Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS

....rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian A...

Top Hepatitis C Treatments Equally Effective

...pies -- peginterferon alfa-2b plus ribavirin, or peginterferon alfa-2a plus ribavirin -- worked in 39.8 percent and 40.9 percent of patients, respectively. Commo...ded by the Schering-Plough Corp., the maker and provider of the study drugs ribavirin and peginterferon alfa-b. More information The U.S. Centers for D...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

... Overview II-2 Pegylated Alpha Interferon Plus ribavirin - The Standard Therapy II-2 Approved Drugs for...onding Graph/Chart) II-2 Alpha Interferons and ribavirin are Here to Stay II-3 Interferon-based Drugs i...he Standards II-4 Viramidine - Next-Generation ribavirin Drug II-4 High Mutation Rates Keep HCV Elusive...

Good news for some hard-to-treat hepatitis C patients

...bination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not respo...fter an initial course of pegylated interferon and ribavirin anti-viral therapy that may last from six months t...ive to initial treatment, consensus interferon and ribavirin worked for about 7 percent of patients given the l...

NEJM study points to new era in hepatitis C treatment

...n of therapy. They compared a 12-week regimen of telaprevir combined with two different durations of the standard therapy -- peginterferon alfa-2a and ribavirin -- to a control group taking 48 weeks of standard therapy alone. Results showed that 67 percent of patients taking telaprevir in combination with stan...

ribavirin in Medical Technology

Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1

Potent Synergy, Activity and Patient Tolerance Support Development of Omega DUROS Continuous Delivery Therapy BARCELONA, Spain, April 12, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced final results from a Phase 2 study of omega interf...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

...etics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by uninfected liver cells. Interestingly, ribavirin is also postulated to have the greatest impact on HCV second phase inhibition, leading us to evaluate CTS-1027 in combination with ribavirin," said St...

Clinical Update - Debio 025 in Hepatitis C

...n with Peg interferon alpha 2a (peg-IFNÿ±2a) and ribavirin in previously null-responder genotype 1 HCV patien...5%) when co-administered with Peg-IFN alpha-2a and ribavirin in previous null responders. "These results...tion with peg-IFNÿ±2a at 180 micrograms/week and ribavirin at 1000/1200 mg/day in genotype 1 chronic HCV pati...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... Combination therapy with peginterferon and ribavirin is a recognized standard of care worldwide for tre...sly failed treatment with any alfa-interferon plus ribavirin combination therapy. A total of 631 patients were...d Duration of Peginterferon Alfa-2b + Weight-Based ribavirin in European and Asian Genotype 2 and 3 Chronic Hep...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...128 for 14 days -- without pegylated interferon or ribavirin -- experienced a median reduction in viral levels ... Combination therapy of pegylated interferon and ribavirin is the current standard of care for HCV. PEGASYS ...in complete product information). Use with ribavirin . Ribavirin, including COPEGUS(R), may cause bir...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...or 1200 mcg, and an active control group that received peginterferon alfa-2a once weekly at a dose of 180 mcg - with all patients receiving daily oral ribavirin concomitantly. In ACHIEVE 2/3, 933 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C were initially assigned to one of three treatm...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... Combination therapy of pegylated interferon and ribavirin is the current standard of care for the hepatitis ...in complete product information). Use with ribavirin . Ribavirin, including COPEGUS (R) , may cause... patients and in female partners of male patients. ribavirin causes hemolytic anemia. The anemia associated wit...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...velopment for the treatment of HCV; (iii) the expectation that ANA598 will be active in long-term studies in combination with pegylated interferon and ribavirin and the ability to dose ANA598 for up to 48 weeks in future combination studies; (iv) the ability of Anadys to transition into Phase II studies of ANA...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

...red to current standard of care, peginterferon and ribavirin for 48 weeks (control group). The results from th... lead-in boceprevir regimen with peginterferon and ribavirin backbone treatment," said Paul Kwo, M.D., associat...t II of the HCV SPRINT-1 study explored a low-dose ribavirin strategy in which boceprevir was given in combinat...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

...ith nonpegylated or pegylated alpha interferon and ribavirin combination therapy, respectively. The response r...PEGINTRON is indicated for use in combination with ribavirin in patients 3 years of age or older, and as monoth...pping PEGINTRON therapy. Use with Ribavirin: ribavirin may cause birth defects and death of the unborn ch...

ribavirin in Biological News

Hepatitis C responds best to combo of ribavirin and interferon, study concludes

A combination of the drugs ribavirin and interferon is more effective in treating hepatitis C than using interferon alone, but it also increases the risk of side effects, according to a new systematic review of recent evidence. "Adding ribavirin to any type of interferon should be considered the ...

Clearance of hepatitis C viral infection after liver transplantation

...s the prerequisite for patients to have a good outcome. To minimize this possibility, patients were traditionally treated with interferon (IFN) and/or ribavirin before LT. Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, PEGylated IFN, in the treatment bef...

Statins stop hepatitis C virus from replicating

... inhibit the replication of the hepatitis C virus (HCV). They could replace ribavirin in combination therapy with interferon. These findings are published in the... statin-treated cells. To evaluate statins as potential replacements for ribavirin in combination therapy, the researchers tested the anti-HCV activities of e...

Researcher studies, treats military with 'silent disease'

...are that person's disease may not progress." The standard treatment--24 to 48 weeks of a once-a-week injection with interferon and several pills of ribavirin each day--are what Sjogren speculated would cause a decrease in quality of the volunteers' lives. "The medications are tough to take," she said. On...

Novel therapy combinations gain ground in treating hepatitis

...amping 400 to 800 mg/d plus pegIFN, or pegIFN with ribavirin as a control group. For the 162 patients who h...a Extended Therapy of 72 Weeks for Peginterferon / ribavirin Relapse Patients with Chronic Hepatitis C [Abstrac...of daily doses of CIFN (consensus interferon) plus ribavirin (RBV) versus pegIFN (pegylated interferon alfa 2a)...

Identification of specific genes predicts which patients will respond to Hepatitis C treatment

...y be helpful in deciding who will respond to treatment of chronic Hepatitis C with the current combination therapy using the synthetic antiviral agent ribavirin and interferon. This treatment can currently get rid of the virus in only roughly 50% of persons infected with genotype 1, the most common genotype in...

ribavirin in Biological Technology

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance o...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

WARRENDALE, Pa., June 16 /PRNewswire/ -- Three Rivers Pharmaceuticals announced today positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University , an...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...ol. Anadys has finalized its protocol and received FDA clearance for the Phase II study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...se II results of the HCV SPRINT-1 study showing that boceprevir, an oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin significantly increased sustained virologic response compared to current standard of care. (Announced April 23) Announced changes to the compa...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

... executive officer of Idenix. "As we work through the second half of the year, we plan to evaluate IDX184 in combination with pegylated interferon and ribavirin in a 14-day dose-ranging study. Additionally, we plan to file investigational new drug applications from our non-nucleoside polymerase inhibitor and p...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

... administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ... alfa-2b) administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3...n alfa-2b administered every four weeks plus daily ribavirin in treatment-naive patients with genotypes 2 and 3...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

...hase II Trial Design Anadys is preparing for the first Phase II trial in hepatitis C patients of ANA598 in combination with interferon-alpha and ribavirin (current standard of care, or SOC) and intends to submit a protocol to the U.S. Federal Drug Administration (FDA) containing the proposed trial design...

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

...nding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chron...f taribavirin: 20 mg/kg, 25 mg/kg and 30 mg/kg vs. ribavirin 800-1400 mg/day. Throughout the 72-week trial, all...e efficacy (sustained virologic response (SVR)) to ribavirin with consistently lower levels of anemia. In addi...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...ults from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients with HCV infection. Data from the first four dosage cohorts of the study were as follows: The combination resulted in sustain...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

...ical benefit (SVR) in HCV patients; (iii) the expectation that ANA598 will be active in long-term studies in combination with pegylated interferon and ribavirin and the ability to dose ANA598 for up to 48 weeks in future combination studies; (iv) the ability of Anadys to transition into Phase II studies of ANA...